Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$77.66

-0.32 (-0.41%)

, ABT

Abbott

$40.59

-0.2 (-0.49%)

08:03
10/18/16
10/18
08:03
10/18/16
08:03

St. Jude Medical, Abbott to to sell part of vascular closure business to Terumo

Abbott (ABT) and St. Jude Medical (STJ) announced an agreement in principle to sell certain products to Terumo Corporation. The transaction reflects a purchase price of approximately $1.12B and is subject to the successful completion of Abbott's acquisition of St. Jude Medical and antitrust regulatory approvals. Abbott, St. Jude Medical and Terumo are bound by the terms of an exclusivity agreement. The divestiture is an all-cash transaction and will include the products globally for St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath. Abbott will retain its vascular closure products, which include the Perclose ProGlide Suture-Mediated Closure System, StarClose SE Vascular Closure System and Prostar XL Percutaneous Vascular Surgical System.Following Abbott's acquisition of St. Jude Medical, the combined business will compete in nearly every area of the cardiovascular market and hold top positions in high-growth segments, including atrial fibrillation, structural heart and heart failure, as well as a leading position in the high-growth neuromodulation market. This combined portfolio will have the depth, breadth and innovation to help patients restore their health, reduce costs for payors and deliver greater value to customers. Abbott expects to mitigate any impact to its adjusted earnings per share projections related to the sale of these assets to Terumo.

STJ

Acquired by ABT

$77.66

-0.32 (-0.41%)

ABT

Abbott

$40.59

-0.2 (-0.49%)

  • 19

    Oct

  • 19

    Oct

  • 26

    Oct

  • 06

    Nov

STJ Acquired by ABT
$77.66

-0.32 (-0.41%)

10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
ABT Abbott
$40.59

-0.2 (-0.49%)

09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.

TODAY'S FREE FLY STORIES

DIS

Disney

$115.18

1.48 (1.30%)

20:11
04/25/17
04/25
20:11
04/25/17
20:11
Periodicals
ESPN layoffs could be harsher than expected, Sporting News says »

Layoffs at Disney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$110.82

2.81 (2.60%)

, AKZOY

AkzoNobel

$30.00

0.27 (0.91%)

20:09
04/25/17
04/25
20:09
04/25/17
20:09
Periodicals
AkzoNobel says analysis of PPG offer to take time, Bloomberg reports »

AkzoNobel (AKZOY)…

PPG

PPG

$110.82

2.81 (2.60%)

AKZOY

AkzoNobel

$30.00

0.27 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

, TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

20:04
04/25/17
04/25
20:04
04/25/17
20:04
Hot Stocks
FCC chairman vows review of media ownership rules »

In a speech to the…

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

CBS

CBS

$66.41

0.46 (0.70%)

NXST

Nexstar

$68.90

0.3 (0.44%)

CMCSA

Comcast

$38.49

0.48 (1.26%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 09

    May

  • 22

    May

  • 23

    May

  • 15

    Jun

FB

Facebook

$146.49

1.02 (0.70%)

19:57
04/25/17
04/25
19:57
04/25/17
19:57
Periodicals
Facebook tests news discovery methods, The Information says »

Facebook is testing new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AVGO

Broadcom

$223.20

1.96 (0.89%)

, BRCD

Brocade

$12.58

0.01 (0.08%)

19:54
04/25/17
04/25
19:54
04/25/17
19:54
Periodicals
Broadcom, Brocade offer behavioral remedies to EU regulators, CTFN says »

Broadcom (AVGO) has…

AVGO

Broadcom

$223.20

1.96 (0.89%)

BRCD

Brocade

$12.58

0.01 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$146.49

1.02 (0.70%)

19:52
04/25/17
04/25
19:52
04/25/17
19:52
Hot Stocks
Facebook tests expanded 'Related Articles' feature »

Facebook announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

19:47
04/25/17
04/25
19:47
04/25/17
19:47
Periodicals
Trump administration considers additional trade actions, WSJ says »

The Trump administration…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

, PEP

PepsiCo

$114.16

-0.16 (-0.14%)

19:25
04/25/17
04/25
19:25
04/25/17
19:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

PEP

PepsiCo

$114.16

-0.16 (-0.14%)

BA

Boeing

$183.51

1.45 (0.80%)

UTX

United Technologies

$116.87

0.55 (0.47%)

TMO

Thermo Fisher

$158.81

1.47 (0.93%)

GD

General Dynamics

$193.24

1.33 (0.69%)

ANTM

Anthem

$172.46

4.05 (2.40%)

NOC

Northrop Grumman

$248.13

-1.01 (-0.41%)

WM

Waste Management

$74.23

0.13 (0.18%)

IR

Ingersoll-Rand

$85.66

1.47 (1.75%)

DPS

Dr Pepper Snapple

$98.41

0.16 (0.16%)

HES

Hess Corp.

$48.64

0.98 (2.06%)

WYN

Wyndham

$92.22

0.43 (0.47%)

FLIR

FLIR Systems

$37.51

0.27 (0.73%)

NDAQ

Nasdaq

$70.53

0.08 (0.11%)

STT

State Street

$80.62

0.83 (1.04%)

APH

Amphenol

$72.18

0.25 (0.35%)

ROK

Rockwell Automation

$160.14

3.19 (2.03%)

BAX

Baxter

$53.21

-0.24 (-0.45%)

NSC

Norfolk Southern

$116.78

-0.27 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 06

    May

  • 11

    May

  • 17

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

  • 15

    Jun

VZ

Verizon

$46.70

-0.35 (-0.74%)

19:20
04/25/17
04/25
19:20
04/25/17
19:20
Hot Stocks
Verizon introduces unlimited prepaid plan »

Verizon announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

NTB

Butterfield

$32.19

0.07 (0.22%)

19:12
04/25/17
04/25
19:12
04/25/17
19:12
Earnings
Butterfield reports Q1 core EPS 70c, consensus 64c »

Reports Q1 revenue $107M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NBIX

Neurocrine

$53.62

1.84 (3.55%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
Neurocrine prices 30-count bottle of Ingrezza at $5,275 »

Neurocrine disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

MNOV

MediciNova

$5.57

0.14 (2.58%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
MediciNova: Survival rate from MN-166 open-label period 'significantly higher' »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FOX

21st Century Fox

$29.89

0.14 (0.47%)

, FOXA

21st Century Fox

$30.61

0.26 (0.86%)

18:50
04/25/17
04/25
18:50
04/25/17
18:50
Periodicals
8 more employees join Fox News lawsuit over race discrimination, FT says »

Eight current and former…

FOX

21st Century Fox

$29.89

0.14 (0.47%)

FOXA

21st Century Fox

$30.61

0.26 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

, CG

Carlyle Group

$16.70

0.05 (0.30%)

18:44
04/25/17
04/25
18:44
04/25/17
18:44
Periodicals
Albany Molecular receives interest from Pamplona, Carlyle, Bloomberg says »

Albany Molecular (AMRI)…

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

CG

Carlyle Group

$16.70

0.05 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 06

    Jun

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:11
04/25/17
04/25
18:11
04/25/17
18:11
Hot Stocks
Pain Therapeutics sees completing additional Remoxy studies by year end »

"As previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:10
04/25/17
04/25
18:10
04/25/17
18:10
Hot Stocks
Breaking Hot Stocks news story on Pain Therapeutics »

Pain Therapeutics backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:09
04/25/17
04/25
18:09
04/25/17
18:09
Earnings
Pain Therapeutics reports Q1 EPS (6c), one estimate (6c) »

Reports Q1 net cash usage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PHG

Philips

$34.69

0.14 (0.41%)

18:04
04/25/17
04/25
18:04
04/25/17
18:04
Hot Stocks
Philips Lighting repurchases 3.5M shares for roughly EUR101M »

Philips Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$22.56

0.26 (1.17%)

, WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

18:03
04/25/17
04/25
18:03
04/25/17
18:03
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

PBF

PBF Energy

$22.56

0.26 (1.17%)

WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

SWC

Stillwater Mining

$17.99

0.09 (0.50%)

SBGL

Sibanye Gold

$8.14

-0.28 (-3.33%)

ARI

Apollo Commercial

$18.93

0.05 (0.26%)

ZLTQ

ZELTIQ

$56.49

-0.005 (-0.01%)

AGN

Allergan

$238.22

1.24 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 31

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:02
04/25/17
04/25
18:02
04/25/17
18:02
Hot Stocks
Frontline says makes new offer to DHT Holdings »

Frontline (FRO) issued…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBI

First Midwest

$24.11

0.16 (0.67%)

18:01
04/25/17
04/25
18:01
04/25/17
18:01
Earnings
First Midwest reports Q1 adjusted EPS 34c, consensus 33c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 17

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:00
04/25/17
04/25
18:00
04/25/17
18:00
Hot Stocks
Breaking Hot Stocks news story on Frontline, DHT Holdings »

Frontline says makes new…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFLY

Shutterfly

$51.46

0.18 (0.35%)

17:58
04/25/17
04/25
17:58
04/25/17
17:58
Hot Stocks
Shutterfly to retire MyPublisher brand and cite in Q2 »

Comment from company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HBNC

Horizon Bancorp

$27.24

0.37 (1.38%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Horizon Bancorp reports Q1 adjusted EPS 34c, consensus 41c »

Reports Q1 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.